Valuation: Scinai Immunotherapeutics Ltd.

Market Cap 1M 871K 812K 746K 1.41M 95.45M 1.43M 9.58M 3.74M 47.71M 3.77M 3.69M 158M P/E 2024 *
-
P/E 2025 -0.2x
Enterprise Value 1.61M 1.4M 1.3M 1.2M 2.26M 153M 2.29M 15.36M 6.01M 76.53M 6.04M 5.91M 254M EV / Sales 2024
4,521,684x
EV / Sales 2025 2,346,088x
Free-Float
0.36%
Yield 2024 *
-
Yield 2025 -
Jun. 15 Scinai Immunotherapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
May. 20 Scinai Immunotherapeutics Ltd. Appoints Eilon Elmalem as Site Head of Yavne Cdmo Facility, Effective June 14, 2026 CI
Apr. 26 Scinai Immunotherapeutics Ltd. announced that it has received $2.5 million in funding CI
Apr. 23 Scinai Immunotherapeutics Ltd. announced that it expects to receive $2.5 million in funding CI
Apr. 06 Scinai completes strategic reorganization to establish dedicated CDMO platform and lean R&D structure; outlines 2026 priorities RE
Apr. 06 Scinai Immunotherapeutics Leverages Strategic Collaboration with Recipharm to Build Integrated Lifecycle CDMO Platform CI
Apr. 01 Scinai reports full-year 2025 results, with cdmo revenues doubling and strategic expansion through Recipharm collaboration RE
Apr. 01 Scinai Immunotherapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
Mar. 31 Scinai Immunotherapeutics Ltd. Auditor Raises 'Going Concern' Doubt CI
Mar. 16 Scinai Immunotherapeutics receives Nasdaq notification regarding minimum bid price RE
Mar. 02 Scinai signs second amendment to Pincell option agreement and submits revised EUR12 million non-dilutive Feng application to advance Pc111 through human proof of concept RE
Feb. 25 Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform CI
Feb. 17 Scinai Immunotherapeutics Ltd. acquired Recipharm Israel Ltd. from Recipharm AB. CI
1 day-8.35%
1 week-5.23%
Current month-8.35%
1 month-7.47%
3 months-61.20%
6 months-72.57%
Current year-64.86%
1 week 0.23
Extreme 0.2302
0.38
1 month 0.21
Extreme 0.214701
0.38
Current year 0.21
Extreme 0.214701
1.12
1 year 0.21
Extreme 0.214701
1.97
3 years 0.21
Extreme 0.214701
13.9
5 years 0.21
Extreme 0.214701
349
10 years 0.21
Extreme 0.214701
6,199.99
Manager TitleAgeSince
Chief Executive Officer 51 2021-03-01
Director of Finance/CFO 55 2006-12-31
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Chairman 77 2019-09-29
Director/Board Member 64 2020-03-23
Director/Board Member 71 2020-03-23
Date Insider Type Main position Quantity % Market Cap.
1/1/23 Other

Director

1,200,000 0.1606%
1/1/23 Other

Director

4,000,000 0.5354%
1/1/23 Other

Chief Financial Officer

880,000 0.1178%
Change 5-day change 1-year change 3-year change Capi.($)
-8.35%-5.23%-83.43%-98.19% 1.08M
-0.68%-0.68%-1.63%+12.86% 48.22B
+6.03%+5.22%+420.33%+519.87% 38.79B
-2.21%-6.07%+24.87%+5.20% 38.41B
+2.94%-2.25%+6.15%+59.69% 34.88B
+1.98%+4.74%+12.19%+41.37% 29.19B
+0.47%-3.87% - - 16.05B
+0.31%+0.72%+32.99%+122.25% 16B
+1.59%+0.44%+3.43%+16.80% 13.53B
-0.98%-12.98%-4.82%-38.09% 12.22B
Average +0.11%+1.07%+45.56%+71.31% 24.73B
Weighted average by Cap. +1.21%+1.55%+78.99%+112.40%

Financials

2024 2025
Net sales 0.66 0.57 0.53 0.49 0.93 62.59 0.94 6.28 2.46 31.29 2.47 2.42 103.67 1.31 1.14 1.06 0.98 1.84 124.71 1.86 12.51 4.89 62.34 4.92 4.82 206.55
Net income 4.8M 4.16M 3.88M 3.57M 6.75M 456M 6.82M 45.78M 17.89M 228M 18.01M 17.62M 756M -8.31M -7.21M -6.73M -6.18M -11.68M -790M -11.81M -79.29M -31M -395M -31.2M -30.51M -1.31B
Net Debt 122K 106K 98.77K 90.73K 172K 11.6M 173K 1.16M 455K 5.8M 458K 448K 19.22M 606K 526K 491K 451K 852K 57.64M 862K 5.78M 2.26M 28.82M 2.28M 2.23M 95.48M
Logo Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Employees
45
Date Price Change Volume
26-08-04 $0.2502 -8.35% 500,663
26-08-03 $0.2730 0.00% 4,884,862
26-07-31 $0.2730 -1.09% 123,861
26-07-30 $0.2760 +3.49% 96,221
26-07-29 $0.2667 +1.02% 67,383

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SCNI Stock